Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$51.20 USD

51.20
2,122,230

+0.77 (1.53%)

Updated Jul 24, 2024 04:00 PM ET

Pre-Market: $52.70 +1.50 (2.93%) 8:52 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (201 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

CES 2018 Promises a Thrilling Year for Gaming Enthusiasts

During CES 2018, a number of companies displayed some extravagant products which are set to change the gaming experience entirely this year.

    Arpita Dutt headshot

    Pharma Stock Roundup: Novo Nordisk Reveals Bid to Acquire Ablynx, Pfizer & Others at Healthcare Conference

    Focus this week was on pipeline updates provided by several companies including Pfizer (PFE) at a healthcare conference while Novo Nordisk's bid to acquire Ablynx also made news.

      Novo Nordisk's Ozempic Gets Canadian Approval for Diabetes

      Novo Nordisk (NVO) announced that Health Canada has approved Ozempic to improve glycemic control in adults with type II diabetes mellitus.

        Emergent Down on '18 View, Posts Preliminary '17 Results

        Emergent (EBS) provides preliminary results for 2017 and its guidance for 2018. The results exceed management's outlook issued in November last year.

          AbbVie's Upadacitinib Gains Breakthrough Therapy Designation

          AbbVie's (ABBV) atopic dermatitis (eczema) candidate, upadacitinib, gets breakthrough therapy status from the FDA.

            Regeneron, Sanofi Expand Investment in Cemiplimab & Dupilumab

            Regeneron (REGN) and partner Sanofi announced that they will expand their investment for the development cemiplimab in oncology, and label expansion of dupilumab in Type II allergic diseases.

              Alnylam, Sanofi Announce Restructuring Deal for RNAi Products

              Alnylam (ALNY) and Sanofi entered into a strategic restructuring of their RNAi therapeutics rare genetic diseases alliance.

                5 Reasons to Pick Emergent as an Investment-Worthy Stock

                Other than a bullish rank, there are several factors that make Emergent (EBS) a solid investment in 2018.

                  Arpita Dutt headshot

                  3 Biotech and Pharma Stocks with FDA Catalysts this January

                  2017 saw the FDA approving 46 novel drugs as well as path-breaking treatments like Novartis's (NVS) Kymriah and Gilead's Yescarta. Here is a look at three companies expecting a decision this January.

                    Protalix (PLX) Fabry Disease Candidate Gets Orphan Status

                    Protalix BioTherapeutics's (PLX) pipeline candidate, PRX-102, gets orphan drug status in Europe which is being developed as a treatment for Fabry disease.

                      BioMarin's (BMRN) Gene Therapy Enters First Phase III Study

                      BioMarin (BMRN) commences the first phase III study to evaluate the 6e13 vg/kg dose of its investigational gene therapy, valoctocogene roxaparvovec, for severe hemophilia A.

                        Why is Alnylam's (ALNY) Stock Up More Than 200% This Year?

                        Alnylam's (ALNY) share price has increased year to date based on impressive progress of its pipeline candidates.

                          Regeneron in Strategic Immuno-Oncology Collaboration With ISA

                          Regeneron Pharmaceuticals (REGN) and ISA Pharmaceuticals inked an agreement to advance ISA101 in combination with cemiplimab.

                            Alnylam/Sanofi Submit MAA in Europe for RNAi Candidate

                            Alnylam (ALNY) and partner Sanofi have submitted a Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment adults with hereditary ATTR amyloidosis with polyneuropathy.

                              Novo Nordisk's (NVO) Semaglutide Gets Positive CHMP Opinion

                              Novo Nordisk (NVO) announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorisation of semaglutide for the treatment of adults with type II diabetes mellitus.

                                Sanofi/Alnylam Say FDA Lifts Clinical Hold on Fitusiran

                                Sanofi (SNY) and Alnylam announced that the FDA has lifted the clinical hold placed on all ongoing studies of its hemophilia candidate, fitusiran.

                                  Mylan Announces IPR Proceedings for Sanofi's Lantus Patents

                                  Mylan (MYL) announced that interpartes review (IPR) proceedings has been initiated by PTAB regarding two Orange Book-listed patents, U.S. Patent Nos. 7,476,652 and 7,713,930 owned by Sanofi.

                                    Cancer Space Update: Roche, Pfizer & Regeneron Make Data Presentations

                                    Several presentations at the annual meeting of the American Society of Hematology grab headlines in the cancer space.

                                      Arpita Dutt headshot

                                      Pharma Stock Roundup: Teva Announces Major Job Cuts, Lilly Provides 2018 Outlook

                                      This week's pharma sector highlights include ASH data, Teva's restructuring announcement and Lilly's (LLY) 2018 outlook.

                                        Lilly Issues Guidance for 2018, New Drugs to Drive Top Line

                                        Eli Lilly (LLY) issues financial guidance for 2018 and also reaffirms the previously issued 2017 projection as well as its long-term expectations.

                                          Regeneron, Sanofi Report Positive Top Line Skin Cancer Data

                                          Regeneron (REGN) and partner Sanofi announced positive top-line results from a pivotal phase II study of skin cancer candidate cemiplimab.

                                            Intersect ENT (XENT) SINUVA Implant Receives FDA Approval

                                            Intersect ENT's (XENT) consistent focus on the chronic sinusitis market is likely to lend the company a competitive edge in the niche space.

                                              Sanofi Wins FDA Approval for Biosimilar of Lilly's Humalog

                                              Sanofi's (SNY) Admelog, a follow-on biologic version of Lilly's Humalog, received FDA approval.

                                                Arpita Dutt headshot

                                                3 Stocks in Focus as Biotech M&A Hopes for 2018 Rise

                                                With tax reform on the horizon, the biotech sector is expected to witness a surge in M&A deals. Here is a look at Juno (JUNO) and two other biotech stocks that could be on the acquisition radar.

                                                  Sanofi Begins Combo Studies on Multiple Myeloma Candidate

                                                  Sanofi (SNY) starts two new phase III studies evaluating isatuximab in combination with other cancer medicines for the treatment of multiple myeloma, a rare blood cancer.